menu
    • menu
    [{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Kyorin Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Imidafenacin","moa":"Muscarinic acetylcholine receptor M3","graph1":"Urology","graph2":"Phase IV","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LG Life Sciences \/ Kyorin Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"LG Life Sciences \/ Kyorin Pharmaceutical"},{"orgOrder":0,"company":"R-Pharm","sponsor":"Synergy Research Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"RUSSIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Imidafenacin","moa":"Muscarinic acetylcholine receptor M3","graph1":"Urology","graph2":"Phase III","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"R-Pharm \/ Synergy Research Inc.","highestDevelopmentStatusID":"10","companyTruncated":"R-Pharm \/ Synergy Research Inc."}]

    Find Clinical Drug Pipeline Developments & Deals for Imidafenacin

    Menu

    Imidafenacin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            R-Pharm

                            Country arrow
                            CTAD25
                            Not Confirmed

                            R-Pharm

                            Country arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Imidafenacin

                            Therapeutic Area : Urology

                            Study Phase : Phase III

                            Sponsor : Synergy Research Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Tre...

                            Details : Uritos (Imidafenacin) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Bladder, Overactive.

                            Product Name : Uritos

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 02, 2018

                            Lead Product(s) : Imidafenacin

                            Therapeutic Area : Urology

                            Highest Development Status : Phase III

                            Sponsor : Synergy Research Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            LG Life Sciences

                            South Korea arrow
                            CTAD25
                            Not Confirmed

                            LG Life Sciences

                            South Korea arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Imidafenacin

                            Therapeutic Area : Urology

                            Study Phase : Phase IV

                            Sponsor : Kyorin Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder

                            Details : Imidafenacin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Urinary Bladder, Overactive.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 16, 2012

                            Lead Product(s) : Imidafenacin

                            Therapeutic Area : Urology

                            Highest Development Status : Phase IV

                            Sponsor : Kyorin Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth